Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis.

Gianluigi Li BassiKristen GibbonsJacky Y SuenHeidi J DaltonNicole WhiteAmanda CorleySally ShrapnelSamuel HintonSimon ForsythJohn G LaffeyEddy FanJonathon P FanningMauro PanigadaRobert BartlettDaniel BrodieAidan BurrellDavide ChiumelloAlyaa ElhazmiMariano EsperattiGiacomo GrasselliCarol HodgsonShingo IchibaCarlos LunaEva MarwaliLaura MersonSrinivas MurthyAlistair NicholMark OginoPaolo PelosiAntoni TorresPauline Yeung NgJohn F Frasernull null

Published in: Critical care (London, England) (2022)

In patients with COVID-19 and moderate-to-severe ARDS, short course of NMBA treatment, applied early, did not significantly improve 90-day mortality and VFD. In the absence of definitive data from clinical trials, NMBAs should be indicated cautiously in this setting.

Keyphrases

clinical trial
acute respiratory distress syndrome
extracorporeal membrane oxygenation
mechanical ventilation
cardiovascular events
risk factors
high intensity
big data
squamous cell carcinoma
early onset
machine learning
cardiovascular disease
radiation therapy
coronary artery disease
phase ii